LNTH Lantheus Holdings Inc

Lantheus to Present at the Wells Fargo Healthcare Conference

Lantheus to Present at the Wells Fargo Healthcare Conference

NORTH BILLERICA, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative diagnostics, targeted therapeutics and artificial intelligence solutions that empower clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Bob Marshall, Chief Financial Officer and Treasurer, and Paul Blanchfield, Chief Operating Officer, will present at the Wells Fargo Healthcare Conference at 8:00 a.m. ET on Thursday, September 8.

To access a live webcast of the presentation, please visit the  section of the Company’s website at . A replay of the webcast will be available on the Company’s website for at least 30 days following the live presentation.

About Lantheus

With more than 60 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden. For more information, visit

Contacts:

Mark Kinarney

Vice President, Investor Relations

978-671-8842

Melissa Downs

Senior Director, Corporate Communications

646-975-2533



EN
01/09/2022

Underlying

LNTHLantheus Holdings Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lantheus Holdings Inc

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.98
WIX WIX.COM LTD.
PCTY Paylocity Holdi... ... (+23)

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

WIX WIX.COM LTD.
PCTY PAYLOCITY HOLDING CORP.
LNTH LANTHEUS HOLDINGS INC
HUBS HUBSPOT INC.
HAE HAEMONETICS CORPORATION
CRM SALESFORCE.COM INC.
CRK COMSTOCK RESOURCES INC.
CPRX CATALYST PHARMACEUTICALS
AR ANTERO RESOURCES CORPORATION
HRB H&R BLOCK INC.
SNAP SNAP INC. CLASS A
CNX CNX RESOURCES CORPORATION
ACI-R-A ADRIATIC CROATIA INTERNATIONAL CLUB D.D.
HPK HIGHPEAK ENERGY INC (A)
ACVA ACV AUCTIONS INC
CHK CHESAPEAKE ENERGY CORP
BRZE BRAZE INC
SG SWEETGREEN INC
MNDY MONDAY COM LTD
IOT SAMSARA INC
KLC KINDERCARE LEARNING COS INC
TEAM ATLASSIAN CORPORATION
SLDE SLIDE INS HLDG INC
08/18/25 August 18, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Reports Second Quarter 2025 Financial Results and Provides Bu...

Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update Recorded second quarter 2025 worldwide revenue of $378.0 million, GAAP fully diluted earnings per share of $1.12, adjusted fully diluted earnings per share of $1.57 and free cash flow of $79.1 millionAnnounced FDA acceptance of NDA for new formulation for piflufolastat F 18 PSMA PET imaging agent with a PDUFA date of March 6, 2026Closed acquisition of Life Molecular Imaging in July, immediately expanding near- and long-term growth profile and commercial portfolio with Neuraceq® (florbetaben F 18 injection), ...

August 6, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Announces FDA Acceptance of NDA for New Formulation for Marke...

Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resiliencePDUFA date set for March 6, 2026 BEDFORD, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the Food and Drug Administration (FDA) has accepted a New Dru...

August 6, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webc...

Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time BEDFORD, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, August 6, 2025, to discuss its financial results and provide a business update for the second quarter of 2025. To access the conference call or webcast, participants should register online at . To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time....

July 23, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Completes Acquisition of Life Molecular Imaging and Appoints ...

Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Developme...

July 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch